June 22, 2015
1 min read

Mayo Clinic, Translational Genomics part of precision medicine trials for metastatic melanoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The Mayo Clinic has teamed with Translational Genomics Research Institute to help launch a multi-institutional, national study in precision medicines to treat BRAF wild-type metastatic melanoma.

“This study is unique in offering more than 20 different treatment options in a single trial,” Alan Bryce, MD, Mayo Clinic investigator for the trial, said in a press release. “By leveraging the power of cancer genomics, we believe we can treat each patient with the best drug for their individual situation. This design offers patients a huge advantage over the old model of treating all patients the same way and only testing one drug at a time.”

Alan Bryce, MD

Alan Bryce

Mayo Clinic, located in Phoenix, is the only clinical site in Arizona to offer the new treatment, sponsored by Stand Up to Cancer and the Melanoma Research Alliance, according to the press release. The Mayo Clinic leadership team includes physicians from locations in Phoenix, Rochester, Minn., and Jacksonville, Fla., where trials will be conducted.

The clinical trials, are being led by Yale University and include seven other institutions: Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit; Biometrics Research Branch, National Cancer Institute, NIH, Rockville, Md.; University of Michigan Comprehensive Cancer Center, Ann Arbor, Mich.; Charles A. Sammons Cancer Center/Baylor University Medical Center, Dallas; Indiana University, Indianapolis; Vanderbilt University, Nashville, Tenn.; and Memorial Sloan-Kettering Cancer Center, New York, the release stated.

The clinical trials will include patients who lack a particular genetic mutation and for whom immune therapy did not work or was not optional. Molecular sequencing will be used to match targeted drugs to genetic altercations present in tumors missing the BRAF mutation, according to the release. The study will compare outcomes with the precision therapy to current treatments.

Reference: www.mayoclinic.org